App-Quantinova.ai

RISK OF COMORBIDITIES FOLLOWING INCIDENT CLINICIAN-DIAGNOSED KNEE OR HIP OSTEOARTHRITIS: A REGISTRY-BASED COHORT STUDY

K. Pihl - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

RISK OF CKD IN MEMBRANOUS AND PROLIFERATIVE LUPUS NEPHRITIS - ANALYSIS OF A NATIONWIDE MULTICENTRE COHORT

F. Farinha - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus nephritis

N/A

RISK OF ANTI-CITRULLINATED PEPTIDE ANTIBODIES AND RHEUMATOID FACTOR IN MALE SMOKERS: DATA FROM KUWAIT REGISTRY FOR RHEUMATIC DISEASES (KRRD)

A. Al-Herz - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

RISK OF OSTEOARTHRITIS IN AN INCIDENT COHORT OF PEOPLE WITH PSORIATIC ARTHRITIS: A POPULATION-BASED COHORT STUDY

R. Charlton - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN SYSTEMIC SCLEROSIS: RESULTS FROM THE OPEN-LABEL PERIOD OF THE PHASE 3 FOCUSSCED TRIAL

D. Khanna - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Scleroderma

Tocilizumab

SAFETY OF INTRAVENOUS IBANDRONIC ACID IN CHRONIC KIDNEY DISEASE: A REAL WORLD EXPERIENCE

J. Southern - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

Ibandronic acid

SEE ME HEAR ME: AN ANCA-ASSOCIATED VASCULITIS PATIENT CO-CREATION INITIATIVE

S. Perera - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Anti-neutrophil cytoplasmic antibody-associated vasculitis

Carvedilol

SECUKINUMAB THERAPY DOES NOT AFFECT NEUTROPHIL HOST DEFENCE IN PSORIATIC ARTHRITIS

A. Cross - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

secukinumab

SECUKINUMAB DOSE ESCALATION ON ACR RESPONSES IN ANTI-TUMOUR NECROSIS FACTOR NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 FUTURE 4 AND FUTURE 5 STUDIES

P. Emery - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

secukinumab

SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES

A. Deodhar - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ankylosing spondylitis

secukinumab

SECUKINUMAB PROVIDES SIGNIFICANT IMPROVEMENT OF SPINAL PAIN IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE 24-WEEK PHASE 3 SKIPPAIN STUDY

D. Poddubnyy - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

secukinumab

SECUKINUMAB IMPROVES CLINICAL AND IMAGING OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL MANIFESTATIONS WITH INADEQUATE RESPONSE TO NSAIDS: WEEK 52 RESULTS FROM THE MAXIMISE TRIAL

X. Baraliakos - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

secukinumab

SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY

I. Mcinnes - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

secukinumab

SERIOUS INFECTION RISK IN PEDIATRIC PATIENTS WITH LOW IMMUNOGLOBULIN LEVELS FOLLOWING RITUXIMAB TREATMENT FOR GRANULOMATOSIS WITH POLYANGIITIS (GPA) OR MICROSCOPIC POLYANGIITIS (MPA)

S. Melega - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Wegener's granulomatosis

Glucocorticoid

SEVERITY OF NAIL PSORIASIS SCORE (SNAPS) IS SENSITIVE TO CHANGE IN A COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH ETANERCEPT

A. Antony - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Etanercept

SHINING LIGHT ON AXIAL SPONDYLOARTHRITIS: DISEASE ACTIVITY AND VITAMIN D. WHAT’S THE LINK?

G. A. Brown - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

Ergocalciferol

SEVERITY OF NAIL PSORIASIS SCORE (SNAPS) DEMONSTRATES LONGITUDINAL CONSTRUCT VALIDITY AGAINST THE MODIFIED NAIL PSORIASIS SEVERITY INDEX (mNAPSI) IN AN OBSERVATIONAL COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS

A. Antony - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

SEX SPECIFIC DIFFERENCES IN EARLY PSORIATIC ARTHRITIS

E. Passia - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

SHOULD A COMBINED RHEUMATOLOGY-PULMONOLOGY INTERSTITIAL LUNG DISEASE SERVICE BE CONFINED TO TERTIARY CENTRES - A SERVICE EVALUATION

K. Salama - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

N/A

SOCIAL CARE USE IN PEOPLE WITH CHRONIC PAIN IN THE UNITED KINGDOM

J. Humphreys - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Chronic pain

N/A

Filters

45280 Abstracts